Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Adult Vaccination Ecosystem in IndiaRelease Date:Quality Improvement Vaccines India Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic DermatitisRelease Date:Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology All Enhancing HCP Education in Maternal VaccinationRelease Date:Education Vaccines Saudi Arabia Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology All Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic DiseasesRelease Date:Education Inflammation & Immunology USA B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology USA Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia AreataRelease Date:Education Inflammation & Immunology USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi ArabiaRelease Date:Research Vaccines Saudi Arabia Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing EquityRelease Date:Education Inflammation & Immunology Australia Title Grant Type Focus Area Country Application Due Date Education of Healthcare Professionals to Provide Appropriate Medical Care for Patients with Atopic DermatitisRelease Date:Education Inflammation & Immunology Japan Enzalutamide in the Treatment of Prostate CancerRelease Date:Partner: National Comprehensive Cancer Network, AstellasResearch Oncology USA Addressing Primary Immunodeficiencies within Minority/Underserved PopulationsRelease Date:Education Hospital USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator Competitive Grant ProgramRelease Date:Quality Improvement Rare Disease USA Patient and Caregiver Awareness of Drug Resistant Infections (United States and Europe)Release Date:Education Hospital All Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research – U.S.Release Date:Research Rare Disease USA Establishment of Hospital-Clinic Collaboration Model for Undiagnosed Rheumatic DiseasesRelease Date:Partner: The Japan College of RheumatologyQuality Improvement Inflammation & Immunology Japan A Quality Improvement Grant Request for Proposals Addressing Social Health Needs in Chronic and Preventative DiseaseQuality Improvement Internal Medicine USA Establishment of Support System for Healthy Life Extension of Patients with CV diseaseRelease Date:Quality Improvement Internal Medicine Japan Racial and Ethnic Disparities in the Menopause ExperienceRelease Date:Education Internal Medicine USA Immunotherapy in Urothelial CarcinomaRelease Date:Partner: Merck KGaA Darmstadt, Germany and EMD SeronoEducation Oncology All Managment of Metabolic Risks that Drive Liver Diseases and Increase Cardiovascular Risk in NASHRelease Date:Education Internal Medicine All